17 February 2026
17 February 2026
The acquisition will combine two portfolios that focus on advancing spine care solutions.
Recruitment is ongoing in China and Australia, with IND clearance now obtained in the US.
Cordex plans to work with German transplant centres on individual NUB applications and expand clinical adoption.
A total of 340 biopsy-confirmed IgAN patients were randomised to daily oral Vanrafia or a placebo for approximately 132 weeks.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
